Leukemia Clinical Trials in Colorado

Showing 901-920 of 1,550 trials

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958

This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table.

Moderate-to-severe Allergic Asthma

Genentech, Inc.3 participantsStarted Nov 2020

Rolling Hills Estates, California, United States • Denver, Colorado, United States • Pembroke Pines, Florida, United States +9 more locations

COMPLETEDPhase 153 miles

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

NCT03483324

A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).

Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia in RemissionMyelodysplastic Syndromes+1 more

Angiocrine Bioscience10 participantsStarted Apr 2018

Duarte, California, United States • Aurora, Colorado, United States • New York, New York, United States

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

Leukemia Trials in Other Cities

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

A Study of LY3023414 in Participants With Advanced Cancer

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

Other Conditions in Colorado